A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features

Shigeta Moriya, Shigeo Oba, Kazuhide Adachi, Yuya Nishiyama, Takuro Hayashi, Shinya Nagahisa, Takafumi Kaito, Shunsuke Nakae, Yuichi Hirose

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Brainstem glioma is impossible to resect completely, and patients with this type of glioma show a poor prognosis. Therefore, a more effective adjuvant therapy is required to prolong survival. Bevacizumab is an endothelial growth factor monoclonal antibody with strong anti-vascular effects, which may suppress tumor progression. We performed a retrospective study of data from 6 patients with brainstem glioma showing malignant features who were treated with bevacizumab. Tumor-associated lesions, as evaluated by T2 weighted or fluid-attenuated inversion-recovery magnetic resonance imaging, were reduced in all patients, although the timing of the start of bevacizumab administration and pretreatment were not uniform. Clinical symptoms improved in 4 patients and progression was inhibited in 2 patients. The Karnofsky performance status improved from 56.7 to 71.7 on average. The median reduction ratio of tumor-associated lesions was 76.3%, but tumor suppression did not last in any of the cases. Furthermore, 5 patients died of tumor progression, and 1 patient died of a complication of necrotizing colitis. The median progression-free survival after bevacizumab administration was 7 months. The median overall survival after diagnosis was 16.5 months. Bevacizumab might be a potential therapeutic option for progressive brainstem gliomas with malignant features.

Original languageEnglish
Pages (from-to)228-233
Number of pages6
JournalJournal of Clinical Neuroscience
Volume47
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Glioma
Brain Stem
Retrospective Studies
Neoplasms
Therapeutics
Endothelial Growth Factors
Karnofsky Performance Status
Survival
Colitis
Bevacizumab
Disease-Free Survival
Blood Vessels
Monoclonal Antibodies
Magnetic Resonance Imaging

All Science Journal Classification (ASJC) codes

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Moriya, Shigeta ; Oba, Shigeo ; Adachi, Kazuhide ; Nishiyama, Yuya ; Hayashi, Takuro ; Nagahisa, Shinya ; Kaito, Takafumi ; Nakae, Shunsuke ; Hirose, Yuichi. / A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features. In: Journal of Clinical Neuroscience. 2018 ; Vol. 47. pp. 228-233.
@article{46f3474012ad4752afe9a02a846c137d,
title = "A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features",
abstract = "Brainstem glioma is impossible to resect completely, and patients with this type of glioma show a poor prognosis. Therefore, a more effective adjuvant therapy is required to prolong survival. Bevacizumab is an endothelial growth factor monoclonal antibody with strong anti-vascular effects, which may suppress tumor progression. We performed a retrospective study of data from 6 patients with brainstem glioma showing malignant features who were treated with bevacizumab. Tumor-associated lesions, as evaluated by T2 weighted or fluid-attenuated inversion-recovery magnetic resonance imaging, were reduced in all patients, although the timing of the start of bevacizumab administration and pretreatment were not uniform. Clinical symptoms improved in 4 patients and progression was inhibited in 2 patients. The Karnofsky performance status improved from 56.7 to 71.7 on average. The median reduction ratio of tumor-associated lesions was 76.3{\%}, but tumor suppression did not last in any of the cases. Furthermore, 5 patients died of tumor progression, and 1 patient died of a complication of necrotizing colitis. The median progression-free survival after bevacizumab administration was 7 months. The median overall survival after diagnosis was 16.5 months. Bevacizumab might be a potential therapeutic option for progressive brainstem gliomas with malignant features.",
author = "Shigeta Moriya and Shigeo Oba and Kazuhide Adachi and Yuya Nishiyama and Takuro Hayashi and Shinya Nagahisa and Takafumi Kaito and Shunsuke Nakae and Yuichi Hirose",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jocn.2017.10.002",
language = "English",
volume = "47",
pages = "228--233",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",

}

A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features. / Moriya, Shigeta; Oba, Shigeo; Adachi, Kazuhide; Nishiyama, Yuya; Hayashi, Takuro; Nagahisa, Shinya; Kaito, Takafumi; Nakae, Shunsuke; Hirose, Yuichi.

In: Journal of Clinical Neuroscience, Vol. 47, 01.01.2018, p. 228-233.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A retrospective study of bevacizumab for treatment of brainstem glioma with malignant features

AU - Moriya, Shigeta

AU - Oba, Shigeo

AU - Adachi, Kazuhide

AU - Nishiyama, Yuya

AU - Hayashi, Takuro

AU - Nagahisa, Shinya

AU - Kaito, Takafumi

AU - Nakae, Shunsuke

AU - Hirose, Yuichi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Brainstem glioma is impossible to resect completely, and patients with this type of glioma show a poor prognosis. Therefore, a more effective adjuvant therapy is required to prolong survival. Bevacizumab is an endothelial growth factor monoclonal antibody with strong anti-vascular effects, which may suppress tumor progression. We performed a retrospective study of data from 6 patients with brainstem glioma showing malignant features who were treated with bevacizumab. Tumor-associated lesions, as evaluated by T2 weighted or fluid-attenuated inversion-recovery magnetic resonance imaging, were reduced in all patients, although the timing of the start of bevacizumab administration and pretreatment were not uniform. Clinical symptoms improved in 4 patients and progression was inhibited in 2 patients. The Karnofsky performance status improved from 56.7 to 71.7 on average. The median reduction ratio of tumor-associated lesions was 76.3%, but tumor suppression did not last in any of the cases. Furthermore, 5 patients died of tumor progression, and 1 patient died of a complication of necrotizing colitis. The median progression-free survival after bevacizumab administration was 7 months. The median overall survival after diagnosis was 16.5 months. Bevacizumab might be a potential therapeutic option for progressive brainstem gliomas with malignant features.

AB - Brainstem glioma is impossible to resect completely, and patients with this type of glioma show a poor prognosis. Therefore, a more effective adjuvant therapy is required to prolong survival. Bevacizumab is an endothelial growth factor monoclonal antibody with strong anti-vascular effects, which may suppress tumor progression. We performed a retrospective study of data from 6 patients with brainstem glioma showing malignant features who were treated with bevacizumab. Tumor-associated lesions, as evaluated by T2 weighted or fluid-attenuated inversion-recovery magnetic resonance imaging, were reduced in all patients, although the timing of the start of bevacizumab administration and pretreatment were not uniform. Clinical symptoms improved in 4 patients and progression was inhibited in 2 patients. The Karnofsky performance status improved from 56.7 to 71.7 on average. The median reduction ratio of tumor-associated lesions was 76.3%, but tumor suppression did not last in any of the cases. Furthermore, 5 patients died of tumor progression, and 1 patient died of a complication of necrotizing colitis. The median progression-free survival after bevacizumab administration was 7 months. The median overall survival after diagnosis was 16.5 months. Bevacizumab might be a potential therapeutic option for progressive brainstem gliomas with malignant features.

UR - http://www.scopus.com/inward/record.url?scp=85031497180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031497180&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2017.10.002

DO - 10.1016/j.jocn.2017.10.002

M3 - Article

C2 - 29050897

AN - SCOPUS:85031497180

VL - 47

SP - 228

EP - 233

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

ER -